Lixte Biotechnology Holdings, Inc. — Bitcoin Treasury & Ethereum Treasury Stock
LIXT
Lixte Biotechnology Holdings, Inc. — Bitcoin Treasury & Ethereum Treasury Stock
LIXTMarket
Market Overview
-
Chart
-
Table
- Price
- Market Cap MCap
| Date | OPEN | HIGH | LOW | CLOSE | VWAP | VOLUME | %CHG | $CHG |
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
About
Lixte Biotechnology Holdings, Inc. Company Overview
Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) is a clinical-stage drug discovery company developing biomarker-targeted therapies, particularly inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents, radiation therapy, and immune-checkpoint blockers across cancer indications. Lixte's pipeline includes the LB-100 series, with recent ovarian cancer trial results showing a 40% disease control rate (8/20 patients) when combined with Dostarlimab. The company raised over $11 million via registered direct offerings and private placement, relocated headquarters to Boca Raton, and holds Bitcoin and Ethereum on its corporate balance sheet.
Key Executives
News & Filings
Featured Posts
View all articlesPress Releases
No press releases found.
SEC Filings
| Form Type | Filed | Accepted | Source |
|---|